Keytruda (pembrolizumab) is a prescription drug that’s used to treat certain forms of cancer. Keytruda comes as an intravenous (IV) infusion (an injection into your vein given over time ...

Trodelvy’s next big NSCLC readout is EVOKE-03, which is testing the Gilead drug with Merck’s PD-1 inhibitor Keytruda in PD-L1-high NSCLC. Started in February 2023, the trial currently bears a ...

Later at the meeting, it will also present the results of the phase 2 EVOKE-02 study of Trodelvy in combination with MSD’s Keytruda (pembrolizumab) in first-line PD-L1-high NSCLC. The two ...

Trodelvy’s withdrawal is one of several conditional approvals that have been rescinded in recent years, most notably among the “PD-1” class of drugs that includes Keytruda and Bristol Myers ...

Sacituzumab govitecan's (Trodelvy) accelerated approval in urothelial cancer will be voluntarily withdrawn, Gilead Sciences ...

Last year, Gilead reported what it said were promising topline results from the EVOKE-02 study of Trodelvy in combination with MSD’s PD-1 inhibitor Keytruda (pembrolizumab) and chemo in patients ...

Trodelvy shows consistent efficacy in metastatic triple-negative breast cancer with a 27.8% ORR and 4.8 months PFS. Enhertu demonstrates promising results in HER2-low patients post-Trodelvy, achieving ...

In a phase 3 trial, more deaths due to adverse events were reported in the Trodelvy arm compared with the chemotherapy arm. Gilead has made the decision to withdraw the accelerated approval of ...

AstraZeneca and Amgen's drug could have a new use after positive Phase 3 study results. Elsewhere, Jazz set new plans for a ...

Opens in a new tab or window The indication for sacituzumab govitecan (Trodelvy) in previously treated ... In patients who are receiving EV/[pembrolizumab (Keytruda)], then obviously the most ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Sacituzumab govitecan's (Trodelvy) accelerated approval in urothelial cancer will be voluntarily withdrawn, Gilead ...